Fig. 3

Elevating SOX2 reversibly inhibits the growth of i-SOX2-DU145 and i-SOX2-ONS76 xenografts. a Subcutaneous i-SOX2-DU145 tumor growth of control and Dox-treated mice. Dox treatment was started and ended at the days indicated. Average tumor volumes are presented for control and Dox-treated groups. b Subcutaneous i-SOX2-ONS76 tumor growth of control and Dox-treated mice. Dox treatment was started and ended at the days indicated. Average tumor volumes are presented for control and Dox-treated groups. c Mitotic figures per high-power field in i-SOX2-DU145 tumors. d Mitotic figures per high-power field in i-SOX2-ONS76 tumors. e Subcutaneous parental DU145 tumor growth of control and Dox-treated mice. Dox treatment was started and stopped at the days indicated. Average tumor volumes are presented for control and Dox-treated groups. f Subcutaneous parental ONS76 tumor growth of control and Dox-treated mice. Dox treatment was started and stopped at the days indicated. Average tumor volumes are presented for control and Dox-treated groups. Error bars represent standard error of the mean; statistical significance was determined by two-tailed student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.005)